Clinical studies have shown that PD‐1/PD‐L1 inhibitors are effective in 30–40% of patients with mRCC.[36] PD‐1/PD‐L1 inhibitors, in combination with TKIs, significantly prolong the survival of patients with RCC.[37] Understanding the mechanisms that regulate PD‐L1 expression in RCC may improve the therapeutic efficacy of PD‐1/PD‐L1 blockade. This evidence concerns the gene CD274 and renal cell carcinoma.